Calidi Biotherapeutics Receives Issuance Of New U.S. Patent Covering Novel SuperNova Technology Platform

7/18/24 8:12:36 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $CLDI alert in real time by email

Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the issuance of a new patent for the company's SuperNova technology, strengthening its intellectual property portfolio and positioning Calidi to advance its CLD-201 program into the clinic.

The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,036,278 titled, "Smallpox Vaccine for Cancer Treatment," directed to Calidi's SuperNova platform composed of adipose-derived mesenchymal stem cells loaded with oncolytic vaccinia virus.

Get the next $CLDI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CLDI

Date	Price Target	Rating	Analyst
11/22/2023	$11.00	Buy	H.C. Wainwright
10/9/2023	$9.00	Outperform	Robert W. Baird

More analyst ratings

$CLDI
Press Releases

Fastest customizable press release news feed in the world

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, presented data at the International Oncolytic Virotherapy Conference (IOVC) and the Society for Immunotherapy of Cancer (SITC) Annual Meeting to support the targeted capabilities of its proprietary RTNova™ systemic enveloped virotherapy technology. This data supports the potential use of RTNova to target every metastatic site in multiple oncology indications including metastatic lung cancer. RTNova is uniquely designed to overcome key challenges in systemic virotherapy, including rapid immun
11/18/24 8:00:00 AM ET
$CLDI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE:CLDI) ("Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the closing of its previously announced public offering of 4,437,869 shares of common stock at $1.69 per share for gross proceeds of approximately $7.5 million. Ladenburg Thalmann & Co. Inc. acted as the exclusive placement agent for this offering. The securities described above public offering were offered pursuant to registration statements on Form S-3 (File No. 333-282456), which were declared effective by the United States Securities and Exchange Commission ("SEC") on Oc
11/15/24 4:05:00 PM ET
$CLDI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it has priced its public offering of 4,437,869 shares of the Company's common stock at a price of $1.69 per share. The closing of the offering is expected to occur on or about November 15, 2024, subject to the satisfaction of customary closing conditions. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent for the offering. The gross proceeds to Calidi from the offering, before deducting the placement agent fees and other offering
11/14/24 8:30:00 AM ET
$CLDI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$CLDI
Financials

Live finance-specific insights

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (NASDAQ:NXL) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Nexalin: https://www.redchip.com/assets/access/nxl_accessCalidi: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Mark White, CEO of Nexalin Technology, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate
10/25/24 9:00:00 AM ET
$CLDI
$NXL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 18, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE:CLDI) and Gorilla Technology Group Inc. (NASDAQ:GRRR) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, October 19, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Calidi: https://www.redchip.com/assets/access/cldi_accessGorilla Technology: https://www.redchip.com/assets/access/grrr_accessIn an exclusive interview, Stephen Thesing, Chief Business Officer of Calidi, appears on the RedChip Small Stocks Big Money™ show on Bloombe
10/18/24 8:45:00 AM ET
$BOXL
$CLDI
$GRRR
Other Consumer Services
Real Estate
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / August 2, 2024 / RedChip Companies will air interviews with GreenPower Motor Company Inc. (NASDAQ:GP) and Calidi Biotherapeutics, Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 3, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:GreenPower Motor: https://www.redchip.com/assets/access/gp_accessCalidi Biotherapeutics: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Fraser Atkinson, CEO of GreenPower, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to
8/2/24 9:00:00 AM ET
$CLDI
$GP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Construction/Ag Equipment/Trucks
Consumer Discretionary

$CLDI
Leadership Updates

Live Leadership Updates

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi's Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the appointment of Dr. George E. Peoples, MD, FACS, adjunct professor of Surgical Oncology at MD Anderson Cancer Center, to the company's Board of Directors, and the addition of Mark Gilbert, MD, scientist emeritus at the National Institutes of Health (NIH), to its Medical Advisory Board Received a new U.S. patent for the company's novel SuperNova technology, positioning Calidi to advance its CLD-201 program into the clinic. The patent covers a unique cancer treatment combining stem cells and a smallpox vaccin
8/13/24 5:37:39 PM ET
$CLDI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Mark Gilbert, MD, scientist emeritus at the National Institutes of Health (NIH), to its Medical Advisory Board. This addition increases the board's membership to eight. Dr. Gilbert most recently served as the Chief of the Neuro-Oncology Branch at NIH from 2014 to 2024. Under Dr. Gilbert's leadership, his team of laboratory and clinical investigators conducted groundbreaking research that advanced science in the brain tumor field. He developed robust clinical tria
7/16/24 8:00:00 AM ET
$CLDI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors
Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Dr. George E. Peoples, MD, FACS, to the company's Board of Directors, effective July 1, 2024. "Dr. Peoples is a highly esteemed figure in the field of cancer immunotherapy, bringing decades of experience in cancer vaccine development and clinical research to our Board," said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics. "Dr. Peoples' pioneering work in cancer immunotherapy and his extensive experience in both clinical and military settings will be invaluable as we advance our portfolio
6/27/24 7:00:00 AM ET
$CLDI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Calidi Biotherapeutics Receives Issuance Of New U.S. Patent Covering Novel SuperNova Technology Platform
Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the issuance of a new patent for the company's SuperNova technology, strengthening its intellectual property portfolio and positioning Calidi to advance its CLD-201 program into the clinic. The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,036,278 titled, "Smallpox Vaccine for Cancer Treatment," directed to Calidi's SuperNova platform composed of adipose-derived mesenchymal stem cells loaded with oncolytic vaccinia virus.
7/18/24 8:12:36 AM ET
$CLDI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Calidi Biotherapeutics Has Been Granted U.S. Patent Number 12,036,278 Titled "Smallpox Vaccine For Cancer Treatment".
https://ppubs.uspto.gov/pubwebapp/external.html?q=(12036278).pn
7/16/24 11:19:16 AM ET
$CLDI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Arhaus, Inc. (NASDAQ:ARHS) fell sharply during Monday's session. Jefferies analyst Jonathan Matuszewski downgraded Arhaus from Buy to Hold and lowered the price target from $22 to $16. Arhaus shares dipped 7.9% to $14.55 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Morphic Holding, Inc. (NASDAQ:MORF) shares jumped 75% to $55.72 after Eli Lilly agreed to buy the company for $57 per share in cash. Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) climbed 71% to $6.97 after jumping around 50% on Friday. SRIVARU Holding Limited (NASDAQ:SVMH) shares climbed 61.3% to $0.2549 after the company announced the deployment of advanced
7/8/24 1:16:55 PM ET
$ARHS
$BENF
$CJET
$CLDI
Other Specialty Stores
Consumer Discretionary
Finance: Consumer Services
Finance

Calidi Biotherapeutics Receives Issuance Of New U.S. Patent Covering Novel SuperNova Technology Platform

Chat with this insight

Recent Analyst Ratings for
$CLDI

$CLDI
Press Releases

Fastest customizable press release news feed in the world

Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

$CLDI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

H.C. Wainwright initiated coverage on Calidi Biotherapeutics with a new price target

Robert W. Baird initiated coverage on Calidi Biotherapeutics with a new price target

$CLDI
SEC Filings

Calidi Biotherapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Calidi Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events

SEC Form 424B5 filed by Calidi Biotherapeutics Inc.

$CLDI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Calidi Biotherapeutics Inc.

SEC Form SC 13G filed by Calidi Biotherapeutics Inc.

$CLDI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Stewart Alan R.

SEC Form 4 filed by Director Leftwich Scott

SEC Form 4 filed by Director Peoples George

$CLDI
Financials

Live finance-specific insights

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

$CLDI
Leadership Updates

Live Leadership Updates

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors

$CLDI
Market Insights

Live Market Insights